Over-expressed twist associates with markers of epithelial mesenchymal transition and predicts poor prognosis in breast cancers via ERK and Akt activation

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zhang, Yong Qu ^a   Wei, Xiao Long ^a   Liang, Yuan Ke ^a   Chen, Wei Ling ^a   Zhang, Fan ^a   Bai, Jing Wen ^a   Qiu, Si Qi ^a   Du, Cai Wen ^a   Huang, Wen He ^a   Zhang, Guo Jun ^a  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VASCULOTROPIN C; VIMENTIN; CADHERIN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR PROTEIN; PROTEIN P53; TUMOR MARKER; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; OVERALL SURVIVAL; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TUMOR VOLUME; UPREGULATION; ADULT; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TWIST-RELATED PROTEIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84942902230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135851     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90. doi:10.3322/caac.20107 PMID: 21296855.
2. Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, et al. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2000; 18(5):1075-83. PMID: 10694560.
3. Mirza NQ, Vlastos G, Meric F, Buchholz TA, Esnaola N, Singletary SE, et al. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Annals of surgical oncology. 2002; 9(3):256-65. PMID: 11923132.
4. Rausei S, Rovera F, Dionigi G, Tornese D, Fachinetti A, Boni L, et al. Predictors of loco-regional recurrence and cancer-related death after breast cancer surgery. The breast journal. 2010; 16 Suppl 1:S29-33. doi:10.1111/j.1524-4741.2010.01000.x PMID: 21050306.
5. Saadai P, Moezzi M, Menes T. Preoperative and intraoperative predictors of positive margins after breast-conserving surgery: a retrospective review. Breast cancer. 2011; 18(3):221-5. doi:10.1007/s12282-011-0262-9 PMID: 21465227.
6. Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JW, et al. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. International journal of radiation oncology, biology, physics. 1999; 45(1):73-83. PMID: 10477009.
7. Mechera R, Viehl CT, Oertli D. Factors predicting in-breast tumor recurrence after breast-conserving surgery. Breast cancer research and treatment. 2009; 116(1):171-7. doi:10.1007/s10549-008-0187-y PMID: 18815880.
8. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(28):4701-8. doi:10.1200/JCO.2008.21.7075 PMID: 19720911.
9. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. The New England journal of medicine. 2002; 347(16):1233-41. doi: 10.1056/NEJMoa022152 PMID: 12393820.
10. Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, et al. Twist expression in patients with cervical cancer is associated with poor disease outcome. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2008; 19(1):81-5. doi:10.1093/annonc/mdm344 PMID: 17925286.
11. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urologic oncology. 2010; 28(5):473-9. doi:10.1016/j.urolonc.2008.12.018 PMID: 19272800.
12. Sun S, Du R, Xia L, Sun W, Zhai Y, Yu Y, et al. Twist is a new prognostic marker for renal survival in patients with chronic kidney disease. American journal of nephrology. 2012; 35(2):141-51. doi:10.1159/000335191 PMID: 22248584.
13. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature reviews Molecular cell biology. 2014; 15(3):178-96. doi:10.1038/nrm3758 PMID: 24556840.
14. Teng Y, Li X. The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms. Clinical & experimental metastasis. 2014; 31(3):367-77. doi:10.1007/s10585- 013-9621-6 PMID: 24158354.
15. Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P, et al. Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC cancer. 2011; 11:73. doi:10.1186/1471-2407-11-73 PMID: 21324165; PubMed Central PMCID: PMC3055233.
16. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Annals of surgical oncology. 2005; 12(6):488-96. doi:10.1245/ASO.2005.04.010 PMID: 15864483.
17. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ. Prognostic significance of hypoxia-inducible factor- 1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009; 64 (12):1082-9. doi:10.1136/thx.2009.115691 PMID: 19778933.
18. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL. N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent nuclear translocation of Twist1. Cancer research. 2006; 66(7):3365-9. doi:10.1158/0008-5472.CAN-05-3401 PMID: 16585154.
19. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW. Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology. 2007; 50(5):648-58. doi:10.1111/j.1365-2559.2007.02665.x PMID: 17394502.
20. Luo GQ, Li JH, Wen JF, Zhou YH, Hu YB, Zhou JH. Effect and mechanism of the Twist gene on invasion and metastasis of gastric carcinoma cells. World journal of gastroenterology: WJG. 2008; 14 (16):2487-93. PMID: 18442194; PubMed Central PMCID: PMC2708358.
21. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117(7):927-39. doi:10.1016/j. cell.2004.06.006 PMID: 15210113.
22. Mironchik Y, Winnard PT Jr., Vesuna F, Kato Y, Wildes F, Pathak AP, et al. Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer research. 2005; 65(23):10801-9. doi:10.1158/0008-5472.CAN-05-0712 PMID: 16322226.
23. Pinho AV, Rooman I, Real FX. p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell cycle. 2011; 10(8):1312-21. PMID: 21490434.
24. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene. 2004; 23(2):474-82. doi:10.1038/sj.onc.1207128 PMID: 14724576.
25. Shiota M, Yokomizo A, Itsumi M, Uchiumi T, Tada Y, Song Y, et al. Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells. BJU international. 2011; 108(2 Pt 2):E142-9. doi:10.1111/j.1464-410X.2010.09810.x PMID: 21083641.
26. Zhuo WL, Wang Y, Zhuo XL, Zhang YS, Chen ZT. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochemical and biophysical research communications. 2008; 369(4):1098-102. doi:10.1016/j.bbrc.2008.02.143 PMID: 18331824.
27. Dong A, Fang Y, Zhang L, Xie J, Wu X, Zhang L, et al. Caffeic acid 3,4-dihydroxy-phenethyl ester induces cancer cell senescence by suppressing twist expression. The Journal of pharmacology and experimental therapeutics. 2011; 339(1):238-47. doi:10.1124/jpet.111.181081 PMID: 21765040.
28. Pai HC, Chang LH, Peng CY, Chang YL, Chen CC, Shen CC, et al. Moscatilin inhibits migration and metastasis of human breast cancer MDA-MB-231 cells through inhibition of Akt and Twist signaling pathway. Journal of molecular medicine. 2013; 91(3):347-56. doi:10.1007/s00109-012-0945-5 PMID: 22961111.
29. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer research. 2003; 63(8):1906-13. PMID: 12702582.
30. Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, et al. Expression of twist and wnt in human breast cancer. Anticancer research. 2004; 24(6):3851-6. PMID: 15736421.
31. Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene. 2010; 29 (24):3554-65. doi:10.1038/onc.2010.115 PMID: 20400976.
32. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. The Journal of biological chemistry. 2008; 283(21):14665-73. doi:10.1074/jbc.M707429200 PMID: 18353781; PubMed Central PMCID: PMC2386910.
33. Hong J, Zhou J, Fu J, He T, Qin J, Wang L, et al. Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer research. 2011; 71 (11):3980-90. doi:10.1158/0008-5472.CAN-10-2914 PMID: 21502402; PubMed Central PMCID: PMC3107354.
34. Li NY, Weber CE, Wai PY, Cuevas BD, Zhang J, Kuo PC, et al. An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines. Surgery. 2013; 154(2):404-10. doi:10.1016/j.surg.2013.05.012 PMID: 23889968.
35. Yang P, Liang SX, Huang WH, Zhang HW, Li XL, Xie LH, et al. Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer. Current molecular medicine. 2014; 14(1):174-84. PMID: 24256053.
36. Wei XL, Dou XW, Bai JW, Luo XR, Qiu SQ, Xi DD, et al. ERalpha inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer. Oncotarget. 2015. PMID: 26023734.
37. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 2007; 26(6):934-44. doi:10.1038/ sj.onc.1209839 PMID: 16862168.
38. Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PloS one. 2012; 7(12):e52675. doi: 10.1371/journal.pone.0052675 PMID: 23300741; PubMed Central PMCID: PMC3531378.
39. Wei X, Zhang D, Dou X, Niu N, Huang W, Bai J, et al. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC cancer. 2014; 14:841. doi:10.1186/1471-2407-14-841 PMID: 25406731; PubMed Central PMCID: PMC4247238.
40. Doble BW, Woodgett JR. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells, tissues, organs. 2007; 185(1-3):73-84. doi:10.1159/000101306 PMID: 17587811.
41. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nature cell biology. 2004; 6(10):931-40. doi:10.1038/ncb1173 PMID: 15448698.
42. 12244302Cohen P, Frame S. The renaissance of GSK3. Nature reviews Molecular cell biology. 2001; 2(10):769-76. doi:10.1038/35096075 PMID: 11584304.
43. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378(6559):785-9. doi:10.1038/ 378785a0 PMID: 8524413.
44. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature medicine. 2002; 8 (10):1153-60. doi:10.1038/nm761 PMID: 12244302.
45. Huang J, Ang L, Liu MQ, Hu HG, Wang J, Zou Q, et al. Serum and tissue expression of gelatinase and Twist in breast cancer. European review for medical and pharmacological sciences. 2014; 18 (18):2662-9. PMID: 25317801.
46. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, et al. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha. Oncogene. 2012; 31 (27):3223-34. doi:10.1038/onc.2011.483 PMID: 22056872; PubMed Central PMCID: PMC3276743.
47. van Nes JG, de Kruijf EM, Putter H, Faratian D, Munro A, Campbell F, et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast cancer research and treatment. 2012; 133(1):49-59. doi:10.1007/s10549-011-1684-y PMID: 21796367.
48. Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, et al. A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer cell. 2012; 22(3):404-15. doi:10.1016/j.ccr.2012.08.003 PMID: 22975381.
49. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer research. 2007; 67(5):1979-87. doi:10.1158/0008-5472.CAN-06-1479 PMID: 17332325.
50. Li J, Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC cancer. 2011; 11:49. doi:10.1186/1471-2407- 11-49 PMID: 21284870; PubMed Central PMCID: PMC3040162.
51. Way TD, Huang JT, Chou CH, Huang CH, Yang MH, Ho CT. Emodin represses TWIST1-induced epithelial- mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the betacatenin and Akt pathways. European journal of cancer. 2014; 50(2):366-78. doi:10.1016/j.ejca.2013.09.025 PMID: 24157255.